Advertisement

Topics

Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results

16:05 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Nine product candidates in clinical trials against eight different targets – – Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017 – – Phase I JCAR017 demonstrates 80% overall response ...

Other Sources for this Article

Juno Therapeutics, Inc.
Investor Relations:
Nicole Keith, 206-566-5521
nikki.keith@junotherapeutics.com
or
Media:
Christopher Williams, 206-566-5660
chris.williams@junotherapeutics.com

NEXT ARTICLE

More From BioPortfolio on "Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...